Long-term Survivorship of Discharged Patients With Malignant Tumor Based on Single-institutional Cancer Registry

Surgery Clinical Trial

Official title:

Studies on Long-term Survivorship of Discharged Patients With Malignant Tumor Based on Fudan University Shanghai Cancer Center Registry（FUCaRe）

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04996732
• Other study ID #: YF-2021-01
• Status: Recruiting
• Start date: January 1, 2008
• Est. completion date: December 31, 2041

Study information

• Verified date: August 2021
• Source: Fudan University
• Contact: Ying Zheng, Dr.
• Phone: +8618121299522
• Email: zhengying[@]fudan.edu.cn
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Real-world studies on long-term prognosis in patients who underwent anti-tumor treatments during hospitalization from a hospital-based cancer registry in china.

Description:

This is a single-center continuous enrollment cohort study. The overall survival and disease-free survival of patients with malignant tumors in the target tumor hospital undergoing surgery, radiotherapy, chemotherapy, and immunotherapy were observed. Follow-up methods include medical records review, telephone call interview, and data linkage to the related provincial death certificate registries. This study will provide real world data-sets for researches on long-term survival and prognosis of cancer patients, and expend exploration on the cancer survival determinants both from clinical and social-economic prospective.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 500000
• Est. completion date: December 31, 2041
• Est. primary completion date: December 31, 2040
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• All patients who completed tumor treatment (including surgery, radiotherapy, chemotherapy, immunotherapy, etc.) due to malignant tumors based on preoperative or intraoperative evaluation in Fudan University Shanghai Cancer Center during the study period.

Exclusion Criteria:

• Patients who have not been treated during hospitalization;
• Patients with non-malignant tumors.

Related Conditions & MeSH terms

• Drug Therapy
• Neoplasms
• Radiotherapy
• Surgery
• Survival

Intervention

Procedure:
• hospitalization
Including various treatments such as surgery, radiotherapy, chemotherapy and immunotherapy during hospitalization

Locations

Country	Name	City	State
China	Fudan University Shanghai Cancer Center	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Fudan University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall survival	Death from any cause	15 years
Secondary	Disease-free survival	the time from treatment to recurrence of cancer, second primary cancer or death	15 years